HARROW, INC.
In the published model solve dated 2026-Q2, anchored at $32.83, HARROW, INC. (HROW) is priced for today's economics sustained for ~26.3 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 27, 2026 from SEC EDGAR filings.
• Harrow is a specialty ophthalmic pharma that has assembled a branded eye-care portfolio (VEVYE, IHEEZO, TRIESENCE, MAXIDEX, IOPIDINE) by acquiring and licensing drugs rather than discovering them, and guided full-year 2026 revenue of $350 million to $365 million [Source: FY2025 results, March 2026]. • The defining risk is the balance sheet: net borrowings of roughly $448 million against only about $95 million of cash, with operating profit covering barely a tenth of interest, leaving almost no
Is HROW overvalued? See what's priced in →
208 institutional managers reported holding HROW in 13F filings for the quarter ended 2026-03-31. Together they hold about 57% of the company; the top 10 hold 36%. 37 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 7.3M shares were sold short as of the 2026-06-15 count, about 20% of shares outstanding (9.9 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
HROW's share count grew 39.3% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at HROW over the trailing three years: 2023: 6 buys totaling $991k; 2024: 7 buys totaling $1.95M. 3 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
HROW's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-10 | -17.4% | -13.3% |
| 2023-11-14 | -36.0% | +18.6% |
| 2024-03-20 | +0.3% | +63.7% |
| 2024-05-14 | +40.0% | +52.8% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
HROW's latest 8-K filings: 2026-09-04 (items 5.02, 9.01); 2026-08-10 (items 2.02, 7.01, 9.01); 2026-08-06 (items 1.01, 7.01, 9.01); 2026-06-22 (items 5.07); 2026-06-03 (items 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.